Chatelut E - Search Results

1

[Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys].

Thomas F, Séronie-Vivien S, Malard L, Chatelut E. Thomas F, et al. Among authors: chatelut e. Therapie. 2007 Mar-Apr;62(2):121-7. doi: 10.2515/therapie:2007019. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582313 French.

2

Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.

Chatelut E, Roche H, Plusquellec Y, Peyrille F, De Biasi J, Pujol A, Canal P, Houin G. Chatelut E, et al. J Pharm Sci. 1991 Aug;80(8):730-4. doi: 10.1002/jps.2600800804. J Pharm Sci. 1991. PMID: 1791530

3

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

4

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R. Chatelut E, et al. J Natl Cancer Inst. 1995 Apr 19;87(8):573-80. doi: 10.1093/jnci/87.8.573. J Natl Cancer Inst. 1995. PMID: 7752255

5

A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

Chatelut E, Chevreau C, Brunner V, Martinez M, Houin G, Bugat R, Canal P. Chatelut E, et al. Cancer Chemother Pharmacol. 1995;35(5):391-6. doi: 10.1007/s002800050252. Cancer Chemother Pharmacol. 1995. PMID: 7850920 Clinical Trial.

6

Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.

Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R. Canal P, et al. Among authors: chatelut e. Cancer Res. 1993 Oct 15;53(20):4850-4. Cancer Res. 1993. PMID: 8402672 Clinical Trial.

7

[Prediction of carboplatin clearance from morphological and biological patient characteristics].

Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R, Canal P. Chatelut E, et al. Bull Cancer. 1995 Nov;82(11):946-53. Bull Cancer. 1995. PMID: 8535021 French.

8

Population pharmacokinetics of carboplatin in children.

Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roché H, Robert A, Newell DR, Canal P. Chatelut E, et al. Clin Pharmacol Ther. 1996 Apr;59(4):436-43. doi: 10.1016/S0009-9236(96)90113-7. Clin Pharmacol Ther. 1996. PMID: 8612389 Clinical Trial.

9

[Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship].

Canal P, Chatelut E. Canal P, et al. Among authors: chatelut e. Bull Cancer. 1996 Apr;83(4):256-65. Bull Cancer. 1996. PMID: 8680077 Review. French.

10

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.

Bénézet S, Guimbaud R, Chatelut E, Chevreau C, Bugat R, Canal P. Bénézet S, et al. Among authors: chatelut e. Ann Oncol. 1997 Jun;8(6):607-9. doi: 10.1023/a:1008259009500. Ann Oncol. 1997. PMID: 9261532

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results